U.K. patient advocates urge antitrust regulator to probe drugmakers

U.K. patient advocates urge antitrust regulator to probe drugmakers


The U.K.’s antitrust regulator has been asked by several patient advocacy groups to investigate several large drugmakers and their U.K. lobbying group for “suspected” and “coordinated” efforts to drive up the prices of medicines.

The backdrop to the complaint has been an ongoing row between the pharmaceutical industry and the U.K. government over mandatory rebates that drug companies are required to pay in order to cap the cost of brand-name medicines for the National Health Service. In the 2023-2024 financial year, NHS spent $18.6 billion on such treatments.

But earlier this year, the government proposed boosting rebates from 10% to 23%, prompting industry criticism that the U.K. is no longer a desirable destination for further investment. In recent weeks, several large pharmaceutical companies — AstraZeneca, Merck, and Eli Lilly — responded by halting or scrapping expansion plans for different research of manufacturing facilities worth a combined $2.6 billion.

STAT+ Exclusive Story

STAT+





This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *